HMA-Venetoclax Induction in Newly Diagnosed AML

NCT07748455 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

AML
AML (Acute Myeloid Leukemia)

Interventions

DRUG: Azacitidine 75 mg/m² SC/IV Days 1-7 + Venetoclax 400 mg orally Days 1-28 (Cycle 1 ramp-up per institutional TLS protocol); 28-day cycles; maximum 2 induction cycles

Sponsor

Pakistan Blood and Marrow Transplant (PBMT) Group